Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associa… Read more
Sagimet Biosciences Inc. Series A Common Stock (SGMT) - Total Liabilities
Latest total liabilities as of September 2025: $9.15 Million USD
Based on the latest financial reports, Sagimet Biosciences Inc. Series A Common Stock (SGMT) has total liabilities worth $9.15 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sagimet Biosciences Inc. Series A Common Stock - Total Liabilities Trend (2019–2024)
This chart illustrates how Sagimet Biosciences Inc. Series A Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sagimet Biosciences Inc. Series A Common Stock Competitors by Total Liabilities
The table below lists competitors of Sagimet Biosciences Inc. Series A Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gesher Acquisition Corp. II
NASDAQ:GSHR
|
USA | $5.20 Million |
|
Greene County Bancorp Inc
NASDAQ:GCBC
|
USA | $2.89 Billion |
|
Magnetic Resources NL
AU:MAU
|
Australia | AU$1.40 Million |
|
Al Aqar Healthcare Reit
KLSE:5116
|
Malaysia | RM788.94 Million |
|
Shenzhen Auto Electric Power Plant Co Ltd
SHE:002227
|
China | CN¥550.77 Million |
|
Izmir Firca Sanayi ve Ticaret
IS:IZFAS
|
Turkey | TL242.09 Million |
|
Gencor Industries Inc
NYSE MKT:GENC
|
USA | $13.67 Million |
|
Is Finansal Kiralama AS
IS:ISFIN
|
Turkey | TL77.20 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Sagimet Biosciences Inc. Series A Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sagimet Biosciences Inc. Series A Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sagimet Biosciences Inc. Series A Common Stock (2019–2024)
The table below shows the annual total liabilities of Sagimet Biosciences Inc. Series A Common Stock from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $4.45 Million | -21.22% |
| 2023-12-31 | $5.65 Million | -97.43% |
| 2022-12-31 | $219.98 Million | +1.24% |
| 2021-12-31 | $217.29 Million | +6.06% |
| 2020-12-31 | $204.87 Million | +50.11% |
| 2019-12-31 | $136.47 Million | -- |